- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
FDA expands indications for SculpSure
The U.S. Food and Drug Administration granted an expanded FDA 510(k) clearance in September for Cynosure’s non-invasive body contouring product, SculpSure.
The U.S. Food and Drug Administration granted an expanded FDA 510(k) clearance in September for Cynosure’s non-invasive body contouring product, SculpSure. This body contouring laser treatment is now cleared to treat the submental area. SculpSure has also been cleared to treat the abdomen, flanks, back, and inner and outer thighs. This treatment uses a laser to raise the temperature of body fat to disrupt and destroy fat cells, which are then naturally and permanently eliminated.
FOR MORE INFORMATION: www.SculpSure.com.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
